Chardan Capital Issues Positive Forecast for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

Lexeo Therapeutics (NASDAQ:LXEO) had its price target boosted by Chardan Capital from $23.00 to $25.00 in a report issued on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

LXEO has been the topic of several other research reports. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Lexeo Therapeutics in a report on Thursday, October 31st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Lexeo Therapeutics has an average rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $7.64 on Wednesday. The firm has a market cap of $252.58 million and a PE ratio of -0.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.38 and a quick ratio of 9.38. The stock’s fifty day moving average price is $9.16 and its two-hundred day moving average price is $12.30. Lexeo Therapeutics has a one year low of $7.47 and a one year high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, hitting the consensus estimate of ($0.64). As a group, research analysts expect that Lexeo Therapeutics will post -2.76 EPS for the current fiscal year.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $977,629.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 12,500 shares of company stock worth $113,300 in the last 90 days. Insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LXEO. BNP Paribas Financial Markets bought a new position in Lexeo Therapeutics in the 1st quarter valued at approximately $75,000. Vanguard Group Inc. increased its position in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after acquiring an additional 65,573 shares during the period. American International Group Inc. bought a new position in shares of Lexeo Therapeutics during the first quarter valued at $79,000. Janus Henderson Group PLC lifted its holdings in shares of Lexeo Therapeutics by 9.0% during the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock worth $39,802,000 after purchasing an additional 210,047 shares during the period. Finally, Artal Group S.A. lifted its holdings in shares of Lexeo Therapeutics by 32.9% during the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after purchasing an additional 198,281 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.